



# UNITED STATES PATENT AND TRADEMARK OFFICE

ch

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/828,398	04/20/2004	Paul E. Luner	PC25686A	4829

28880 7590 04/12/2007  
WARNER-LAMBERT COMPANY  
2800 PLYMOUTH RD  
ANN ARBOR, MI 48105

EXAMINER
----------

AHMED, HASAN SYED

ART UNIT	PAPER NUMBER
----------	--------------

1615

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
31 DAYS	04/12/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

**Office Action Summary**

Application No.

10/828,398

Applicant(s)

LUNER ET AL.

Examiner

Hasan S. Ahmed

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-42 is/are pending in the application:
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-42 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_.

- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_.

## DETAILED ACTION

### *Election/Restrictions*

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-7 and 10-17, drawn to a dry-granulated pharmaceutical composition comprising atorvastatin, classified in class 424, subclass 1.13.
- II. Claims 1, 5, 6, 8, 9, and 18-20, drawn to a dry-granulated pharmaceutical composition comprising atorvastatin and at least one other active drug, classified in class 424, subclass 1.13.
- III. Claims 22-37, drawn to a method of preparing a pharmaceutical composition comprising atorvastatin, classified in class 424, subclass 1.13.
- IV. Claims 1 and 38, drawn to a method of preparing a pharmaceutical composition comprising atorvastatin and at least one other active drug, classified in class 424, subclass 1.13.
- V. Claim 1 and 39, drawn to a method of treatment, classified in class 424, subclass 1.13.
- VI. Claims 40-42, drawn to a kit, classified in class 424, subclass 1.13.

\* \* \* \* \*

Claim 1 links inventions I, II, IV and V. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim, claim 1. Upon the indication of allowability of the linking claims, the restriction

Art Unit: 1615

as to the linked inventions shall be withdrawn and any claims depending from or otherwise requiring all the limitations of the allowable linking claim will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104. Claims that require all the limitations of an allowable linking claim will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicants are advised that if any claim(s) including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

\* \* \* \* \*

The inventions are distinct, each from the other for the following reasons:

***Groups I-VI***

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, Group I is directed to a pharmaceutical composition

Art Unit: 1615

comprising atorvastatin while Group II is directed to a pharmaceutical composition comprising atorvastatin and at least one additional active drug.

Inventions I and III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the process as claimed can be used to make another and materially different product, such as a pharmaceutical composition not comprising atorvastatin.

Inventions I and IV are unrelated. In the instant case, Group I is directed to a pharmaceutical composition comprising atorvastatin while Group IV is directed to a process of making a pharmaceutical composition comprising atorvastatin and at least one additional active drug.

Inventions I and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case, the process for using the product as claimed can be practiced with another materially different product, such as a transdermal formulation.

Inventions I and VI are unrelated. In the instant case, Group I is directed to a pharmaceutical composition comprising atorvastatin while Group VI is directed to a kit.

***Groups II-VI***

Inventions II and III are unrelated. In the instant case, Group II is directed to a pharmaceutical composition comprising atorvastatin and at least one additional active drug while Group III is directed to a process of making a pharmaceutical composition comprising atorvastatin.

Inventions II and IV are related as process of making and product made. In the instant case the process as claimed can be used to make another and materially different product, such as a pharmaceutical composition not comprising atorvastatin.

Inventions II and V are unrelated. In the instant case, Group II is directed to a pharmaceutical composition comprising atorvastatin and at least one additional active drug while Group V is directed to a method of treating using a pharmaceutical composition comprising atorvastatin as the sole active drug.

Inventions II and VI are unrelated. In the instant case, Group II is directed to a pharmaceutical composition comprising atorvastatin and at least one additional active drug while Group VI is directed to a kit.

***Groups III-VI***

Inventions III and IV are unrelated. In the instant case, Group III is directed to a process of making a pharmaceutical composition comprising atorvastatin while Group IV is directed to a process of making a pharmaceutical composition comprising atorvastatin and at least one additional active drug.

Inventions III and V are unrelated. In the instant case, Group III is directed to a process of making a pharmaceutical composition comprising atorvastatin

Art Unit: 1615

while Group V is directed to a method of treating using a pharmaceutical composition comprising atorvastatin.

Inventions III and VI are unrelated. In the instant case, Group III is directed to a process of making a pharmaceutical composition comprising atorvastatin while Group VI is directed to a kit.

***Groups IV-VI***

Inventions IV and V are unrelated. In the instant case, Group IV is directed to a process of making a pharmaceutical composition comprising atorvastatin and at least one additional active drug while Group V is directed to a method of treating using a pharmaceutical composition comprising atorvastatin as the sole active drug.

Inventions IV and VI are unrelated. In the instant case, Group IV is directed to a process of making a pharmaceutical composition comprising atorvastatin and at least one additional active drug while Group VI is directed to a kit.

***Groups V and VI***

Inventions V and VI are unrelated. In the instant case, Group V is directed to a method of treating using a pharmaceutical composition comprising atorvastatin as the sole active drug while Group VI is directed to a kit.

\* \* \* \* \*

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed a nonelected process invention must

Art Unit: 1615

require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

\* \* \* \* \*

This application contains claims directed to the following patentably distinct species:

Group III:

- Election of a method of compression:
  - a. roller compactor (claim 23)
  - b. tablet press (claim 24)

\* \* \* \* \*

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 1 is generic.

\* \* \* \* \*



Art Unit: 1615

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

\* \* \* \* \*

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

\* \* \* \* \*

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

\* \* \* \* \*

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Art Unit: 1615

Should Applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

★


***Correspondence***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hasan S. Ahmed whose telephone number is 571-272-4792. The examiner can normally be reached on 9am - 5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael P. Woodward can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
HUMERA N. SHEIKH  
PRIMARY EXAMINER